AceLink consists of a seasoned team of drug development professionals, consultants, and advisors with a rich knowledge of glycolipid biology, rare genetic diseases, and drug development. We collaborate with an extensive network of experienced contract research organizations, academics, and key opinion leaders. This business model allows us to efficiently transform scientific discoveries into impactful new therapies.
About AceLink’s lead programs:
AL1211 is a non-brain penetrant glucosylceramide synthase (GCS) inhibitor with unique and superior properties to other GCS inhibitors currently in development. AL1211 has completed Phase 1 and has started Phase 2 trials for patients with Fabry disease. AL1211 is also being developed for type I Gaucher disease (non-neuronopathic). More on AL1211
AL0804 is a highly brain penetrant GCS inhibitor being developed for the treatment of neuronopathic glycolipid storage diseases including Gaucher disease (Type II and III), GM2 gangliosidosis (Tay-Sachs and Sandhoff disease), GM1 gangliosidosis, and certain genetic forms of Parkinson’s disease. More on AL0804
AL1311 is a highly potent NRF2 activator that is being developed for Autosomal Dominant Polycystic Kidney disease (ADPKD). More on AL1311